Laboratorio Farmaceutico Erfo (ERFO) Stock Overview
Engages in the formulation and production of food supplements in Italy. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
+ 1 more risk
ERFO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Laboratorio Farmaceutico Erfo S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.70 |
| 52 Week High | €1.73 |
| 52 Week Low | €0.88 |
| Beta | 1.43 |
| 1 Month Change | 12.96% |
| 3 Month Change | 30.77% |
| 1 Year Change | 67.49% |
| 3 Year Change | 21.86% |
| 5 Year Change | n/a |
| Change since IPO | -5.56% |
Recent News & Updates
Laboratorio Farmaceutico Erfo S.p.A. (BIT:ERFO) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable
Aug 29
Is There Now An Opportunity In Laboratorio Farmaceutico Erfo S.p.A. (BIT:ERFO)?
Aug 19Recent updates
Laboratorio Farmaceutico Erfo S.p.A. (BIT:ERFO) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable
Aug 29Is There Now An Opportunity In Laboratorio Farmaceutico Erfo S.p.A. (BIT:ERFO)?
Aug 19Laboratorio Farmaceutico Erfo (BIT:ERFO) Might Be Having Difficulty Using Its Capital Effectively
Jul 02Laboratorio Farmaceutico Erfo S.p.A.'s (BIT:ERFO) P/E Still Appears To Be Reasonable
May 22Is It Too Late To Consider Buying Laboratorio Farmaceutico Erfo S.p.A. (BIT:ERFO)?
Feb 20Is Now An Opportune Moment To Examine Laboratorio Farmaceutico Erfo S.p.A. (BIT:ERFO)?
Aug 17Shareholder Returns
| ERFO | IT Personal Products | IT Market | |
|---|---|---|---|
| 7D | 16.4% | 1.4% | 1.8% |
| 1Y | 67.5% | -8.8% | 27.2% |
Return vs Industry: ERFO exceeded the Italian Personal Products industry which returned -8.8% over the past year.
Return vs Market: ERFO exceeded the Italian Market which returned 27.2% over the past year.
Price Volatility
| ERFO volatility | |
|---|---|
| ERFO Average Weekly Movement | 7.8% |
| Personal Products Industry Average Movement | 4.7% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IT Market | 7.9% |
| 10% least volatile stocks in IT Market | 2.5% |
Stable Share Price: ERFO's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: ERFO's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 41 | Alessandro Cute | www.erfo.it |
Laboratorio Farmaceutico Erfo S.p.A. engages in the formulation and production of food supplements in Italy. It produces various types of pharmaceutical forms, such as bottles, single-dose vials and bottles, capsules, tablets, and sachets under the Diètnatural and Gianopharma brands, as well as private label brands. The company offers custom formula creation, regulatory advice, graphics, and packaging services.
Laboratorio Farmaceutico Erfo S.p.A. Fundamentals Summary
| ERFO fundamental statistics | |
|---|---|
| Market cap | €14.58m |
| Earnings (TTM) | €373.56k |
| Revenue (TTM) | €7.91m |
Is ERFO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERFO income statement (TTM) | |
|---|---|
| Revenue | €7.91m |
| Cost of Revenue | €4.78m |
| Gross Profit | €3.13m |
| Other Expenses | €2.75m |
| Earnings | €373.56k |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.044 |
| Gross Margin | 39.53% |
| Net Profit Margin | 4.72% |
| Debt/Equity Ratio | 18.0% |
How did ERFO perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 14:26 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Laboratorio Farmaceutico Erfo S.p.A. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Tempestini | KT & Partners Srl |
| Federica Fiorenza | KT & Partners Srl |
| Fusun Bektas | KT & Partners Srl |